Fig. 3: In vivo prophylactic and therapeutic activity of the bispecific antibody G7-Fc via different administration routes. | Nature Communications

Fig. 3: In vivo prophylactic and therapeutic activity of the bispecific antibody G7-Fc via different administration routes.

From: A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses

Fig. 3

a Schematic diagram of G7-Fc in the prevention (abbreviation P) and treatment (abbreviation T) of XBB.1 infection. G7-Fc was administrated intraperitoneally (abbreviation i.p.) or intranasally (abbreviation i.n.). b, c Viral titers (FFU, focus-forming units) of lung tissue of b K8-ACE2 mice (n = 5) and c BALB/c mice (n = 4) were determined after 48 h post-infection. Each data point represents an individual mouse within the respective groups. The mean ± SEM of all data points are shown in (b, c). Statistical significance was analyzed using a two-sided t-test in (b, c) with Prism software (version 9, GraphPad Software), and p < 0.0001 is expressed as ***. Source data of b, c are provided in the Source Data file. The icon in a were created using Adobe Illustrator, and the schematic diagram was created using Microsoft Office PowerPoint.

Back to article page